Afferent block for Diastolic Heart Failure

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Diastolic Heart FailureAfferent block - Procedure
Eligibility
21 - 85
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help researchers understand why patients with heart failure and preserved ejection fraction (HFpEF) are intolerant to exercise, and if regular physical activity can help improve this.

Eligible Conditions
  • Diastolic Heart Failure

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

0 Primary · 1 Secondary · Reporting Duration: 12 weeks

12 weeks
femoral blood flow

Trial Safety

Trial Design

3 Treatment Groups

Afferent effect on fatigue
1 of 3
Afferent effect on hemodynamics
1 of 3
Effect of cardiac rehab
1 of 3

Experimental Treatment

50 Total Participants · 3 Treatment Groups

Primary Treatment: Afferent block · No Placebo Group · N/A

Afferent effect on fatigue
Procedure
Experimental Group · 1 Intervention: Afferent block · Intervention Types: Procedure
Afferent effect on hemodynamics
Procedure
Experimental Group · 1 Intervention: Afferent block · Intervention Types: Procedure
Effect of cardiac rehab
Procedure
Experimental Group · 1 Intervention: Afferent block · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,485 Previous Clinical Trials
2,742,169 Total Patients Enrolled
Markus Amann, PhDPrincipal InvestigatorVA Salt Lake City Health Care System, Salt Lake City, UT
2 Previous Clinical Trials
176 Total Patients Enrolled

Eligibility Criteria

Age 21 - 85 · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: